Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 AlteredExpression group BEFREE Loss of Skp2 resulted in a striking decrease of Ezh2 levels in Pten/Trp53 double-null MEFs and in prostate tumors of Pten/Trp53 double-null mutant mice. 27869166 2017
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 AlteredExpression group BEFREE Chromatin regulators ANCCA and EZH2 are overexpressed in prostate cancer and play crucial roles in androgen-stimulated and castration-refractory prostate tumor growth and survival. 23038103 2013
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group BEFREE Polycomb Group protein enhancer of zeste 2 (EZH2) was found to be overexpressed in metastatic prostate tumors, and is considered an excellent candidate for such a biomarker. 20087897 2010
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group BEFREE UHRF1 expression was negatively correlated with several tumour suppressor genes and positively with the histone methyltransferase (HMT) EZH2 both in prostate tumours and cell lines. 22330138 2012
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group CTD_human Down-regulation of the histone methyltransferase EZH2 contributes to the epigenetic programming of decidualizing human endometrial stromal cells. 21903722 2011
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group CTD_human Integrative molecular concept modeling of prostate cancer progression. 17173048 2007
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group CTD_human Androgen induces expression of the multidrug resistance protein gene MRP4 in prostate cancer cells. 17003774 2007
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group LHGDN Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. 17134822 2007
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group LHGDN The Polycomb Group protein EZH2 regulates actin polymerization in human prostate cancer cells. 18095286 2008
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 AlteredExpression group LHGDN Identification of enhancer of zeste homolog 2 expression in peripheral circulating tumor cells in metastatic prostate cancer patients: a preliminary study. 18159594 2007
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 AlteredExpression group LHGDN The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. 16575874 2006
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 AlteredExpression group LHGDN The polycomb group protein EZH2 is involved in progression of prostate cancer. 12374981 2002
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group LHGDN The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2. 17237810 2007
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group LHGDN Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. 16963837 2006
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 PosttranslationalModification group LHGDN Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer. 18637271 2007
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 AlteredExpression group LHGDN Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. 15817459 2005